PAMP
ENGNW icon

Polar Asset Management Partners’s enGene Therapeutics Warrants ENGNW Stock Holding History

Polar Asset Management Partners’s Portfolio ENGNW Stock Details ENGNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-97,391
Closed – – 755
2024
Q2 		$0 Hold
97,391
– – ﹤0.01% 740
2024
Q1 		$517K Sell
97,391
-83,332
-46% -$254K 0.01% 464
2023
Q4 		$210K Buy
+180,723
New +$139K ﹤0.01% 488

Other funds holding ENGNW

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Polar Asset Management Partners's ENGNW Position: Q3 2024 in Review

Polar Asset Management Partners sold out of enGene Therapeutics Warrants (ENGNW) in Q3 2024, closing a stake of 97,391 shares.

Polar Asset Management Partners first reported a position in ENGNW in Q4 2023 and held it in 3 quarters. The position peaked at $517K in Q1 2024. 14 funds tracked by Wall St. Rank hold ENGNW as of Q3 2024.

  • Polar Asset Management Partners reported no remaining enGene Therapeutics Warrants position as of Q3 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 97,391 enGene Therapeutics Warrants shares in Q3 2024.
  • Polar Asset Management Partners first reported a position in enGene Therapeutics Warrants in Q4 2023 and held it in 3 quarters.
  • Polar Asset Management Partners's enGene Therapeutics Warrants position peaked at $517K in Q1 2024.
  • 14 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q3 2024.

Based on Polar Asset Management Partners's 13F filing for Q3 2024, filed 14 Nov 2024.